Skip to main content
. 2021 May 18;6:197. doi: 10.1038/s41392-021-00611-6

Table 1.

Characteristics of the COVID-19 patients

Total population
n = 545
Peak analysis
n = 328
Decay analysis
n = 194
6-month visit
n = 197
Age, year, Mean ± sd 50.9 ± 15.0 49.9 ± 14.5 52.2 ± 13.9 55.9 ± 13.3
Age, N(%)
18 ~ 40 year 140 (25.7%) 88 (26.8%) 41 (21.1%) 28 (14.2%)
41 ~ 60 year 262 (48.1%) 159 (48.5%) 98 (50.5%) 93 (47.2%)
61 ~ 90 year 143 (26.2%) 81 (24.7%) 55 (28.4%) 76 (38.6%)
Gender, N (%)
female 259 (47.5%) 155 (47.3%) 86 (44.3%) 92 (46.7%)
male 286 (52.5%) 173 (52.7%) 108 (55.7%) 105 (53.3%)
Disease severitya, N (%)
mild 491 (90.1%) 304 (92.7%) 181 (93.3%) 181 (91.9%)
severe 54 (9.9%) 24 (7.3%) 13 (6.7%) 16 (8.1%)
Number of antibody testing, N (%)
1 166 (30.5%) 26 (7.9%) 0 (0%) 26 (13.2%)
2 111 (20.4%) 76 (23.2%) 31 (16.0%) 24 (12.2%)
3 144 (26.4%) 126 (38.4%) 87 (44.8%) 76 (38.6%)
≥4 124 (22.8%) 100 (30.5%) 76 (39.2%) 71 (36.0%)
Number of RT-PCR testing, Mean ± sd 7.0 ± 2.3 7.3 ± 2.2 7.2 ± 2.1 6.9 ± 2.1
Days from symptom to PCR positiveb, Mean ± sd 11.7 ± 8.4 12.6 ± 8.1 13.1 ± 8.1 12.3 ± 8.0
Duration of COVID-19c, day, Mean ± sd 25.6 ± 13.1 26.8 ± 12.6 29.8 ± 12.4 28.7 ± 13.2
Length of follow upd, days 62 (45, 175) 63 (49, 179) 174 (62, 183) 180 (174, 184)
Use of hydroxychloroquinee, N (%) 49 (13.5%) 39 (14.1%) 22 (12.8%) 21 (15.1%)
Use of glucocorticoidse, N (%) 178 (48.9%) 135 (48.9%) 90 (52.3%) 79 (56.8%)

a Severe COVID-19 was defined as need for ICU, respiratory failure, mechanical ventilation, or death.

b in symptomatic patients. Symptoms considered included fever, coughing, sore throat, tiredness, dyspnea, aches and pains, diarrhea, and loss of taste or smell.

c defined as days from onset of symptoms to virus shedding (RT-PCR test turning from positive to negative).

d presented as median (25th, 75th percentile).

e in patients with medical information.